Doxorubicin Hydrochloride CAS 25316-40-9 API USP Standard Factory High-dị ọcha
Onye nrụpụta nwere ịdị ọcha dị elu yana ogo kwụsiri ike
Aha kemịkal: Doxorubicin Hydrochloride
Ọkụ: 25316-40-9
Ihe Ngwọta Ọgwụ Antitumor.Na-egbochi DNA Topoisomerase II
API Ogo dị elu, mmepụta azụmahịa
Aha Chemical | Doxorubicin Hydrochloride |
Ụdị okwu | Doxorubicin HCl;Adriamycin HCL;Hydroxydaunorubicin Hydrochloride |
Nọmba CAS | 25316-40-9 |
Nọmba CAT | RF-API38 |
Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
Usoro ihe omimi | C27H30ClNO11 |
Ibu molekụla | 579.98 |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Orange-Red ma ọ bụ Red Crystalline ntụ ntụ;Enweghị ihe akaebe a na-ahụ anya nke mmetọ site na ihe si mba ọzọ |
Solubility | Soluble na mmiri na methanol;obere soluble na ethanol;ihe fọrọ nke nta ka ọ bụrụ ihe na-adịghị ike so ya na acetone |
njirimara A | Ụdị ụdịdị IR dabara na ụdịdị IR nke ọkọlọtọ ntụaka |
njirimara B | Oge njide nke elu doxorubicin na chromatogram nke nkwadebe Assay kwekọrọ na chromatogram nke nkwadebe Standard, dị ka enwetara na Assay. |
pH | 4.0-5.5 |
Ọdịnaya Mmiri | ≤4.0% |
Ihe ndị emetụtara | |
adịghị ọcha A (Doxorubicinol) | ≤0.50% |
Ọdịghị ọcha ọ bụla ọzọ amabeghị | ≤0.20% |
Mgbakọta adịghị ọcha amabeghị | ≤0.50% |
Mgbakọta adịghị ọcha | ≤1.0% |
Nyocha | 98.0% ~ 102.0% nke C27H30ClNO11 gbakọọ na anhydrous, ihe mgbaze na-enweghị ndabere |
Ihe mgbaze fọdụrụnụ | |
Acetone | ≤0.50% |
Acetone + ethanol | ≤2.5% |
Methanol | ≤0.30% |
Dichloromethane | ≤0.06% |
Nlele ọkọlọtọ | Ụkpụrụ ntụaka nke United States Pharmacopeia (USP). |
Ojiji | Ngwakọta ọgwụ na-arụ ọrụ (API) |
ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.
Shanghai Ruifu Chemical Co., Ltd. bụ onye na-emepụta ihe na onye na-ebubata Doxorubicin Hydrochloride (CAS: 25316-40-9) nwere àgwà dị elu.Doxorubicin hydrochloride, ọgwụ nje anthracycline cytotoxic, bụ ihe na-egbochi ọrịa kansa chemotherapy.Doxorubicin hydrochloride bụ ike mmadụ DNA topoisomerase I na topoisomerase II inhibitor nwere IC50s nke 0.8 μM na 2.67 μM, n'otu n'otu.Doxorubicin hydrochloride na-ebute apoptosis na autophagy.Doxorubicin bụ onye na-ahụ maka antitumor nwere ike na-arụ ọrụ megide ụdị ọrịa ọjọọ dị iche iche, gụnyere leukemias, sarcomas, ọrịa ara ara, obere ọrịa kansa akpa ume cell na ọrịa cancer ovarian.